Trim32 regulation of PKC-zeta in atopic dermatitis
Trim32 对特应性皮炎中 PKC-zeta 的调节
基本信息
- 批准号:10094052
- 负责人:
- 金额:$ 35.88万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-03 至 2023-01-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAgonistAmino Acid MotifsAntiviral AgentsAtopic DermatitisB-LymphocytesBacterial InfectionsBiopsyCell LineageCellsClinicClinicalCompetenceDefectDependenceDermalDevelopmentDiseaseElectron MicroscopyEosinophiliaEventGenesGenetic PolymorphismGoalsHelper-Inducer T-LymphocyteHomeostasisHumanHypersensitivityIgEImage CytometryImaging technologyImiquimodImmuneImmune responseImmune signalingImmunityImmunoglobulin Class SwitchingImmunohistochemistryIn VitroInfectionInfiltrationInflammatoryInflammatory ResponseInterleukin-13Interleukin-4Interleukin-5InterventionKnockout MiceLesionLinkMeasuresMediatingMicroscopyModelingModificationMolecularMolecular StructureMusNatural ImmunityPRKCA genePathogenesisPathologyPathway interactionsPatientsPattern RecognitionPhenotypePhosphorylationPhosphorylation SitePredispositionProductionProtein AnalysisProtein KinaseProteinsPsoriasisRecording of previous eventsRegulationRegulatory PathwayResolutionRoleSamplingSerumSeveritiesSeverity of illnessSignal PathwaySignal TransductionSkinStructureSymptomsT cell differentiationT-LymphocyteTLR1 geneTRIM MotifTestingToll-like receptorsTopical applicationValidationViral PhysiologyVirus Diseasesbasechemokinechronic inflammatory skincytokinedefined contributiondimereosinophilfilaggrinimprovedinsightkeratinocytelight microscopymast cellmouse modelnovelpathogenpredictive testprotein activationprotein kinase C zetaresponseskin disorderskin lesionsuccesstreatment responseubiquitin-protein ligase
项目摘要
PROJECT SUMMARY
Atopic dermatitis (AD) is an inflammatory skin disease with compromised innate immunity as indicated by
susceptibility to bacterial and viral infection. Despite the identification of genetic polymorphisms in genes in the
innate immune signaling pathways, such as TLR1/2/6/9 and NOD1/2, the role of defective innate immunity in
AD pathogenesis remains poorly understood. In this study, we provide new evidence to support the
contribution of defective innate immunity in Th2 activation and AD pathogenesis with Trim32 knockout mice as
a model. In response to topical application of imiquimod, a toll-like receptor agonist used in an established
psoriasis model, we observed that Trim32-deficient mice instead developed AD-like phenotypes, including
dermal infiltration of eosinophils and mast cells, increased Th2 cytokine production, and elevated serum IgE,
compared to the expected Th17 response in Trim32-competent wild type littermates. Based upon this, we
hypothesize that Trim32 (an E3 ubiquitin ligase with innate anti-viral activity) regulates homeostasis in the host
response to infection and, further, that defects in Trim32 pathway proteins or functionality can predispose to
Th2 atopic phenotypes. In seeking Trim32 substrate proteins potentially responsible for atopic features in these
mice and in human AD, we provide novel evidence for Trim32 regulation of protein kinase PKCζ, a known
Stat6 activator of a signaling cascade culminating in IL-4/IL-5 expression in T cells and IgE production by B
cells in allergy models in mice. We therefore propose to address the role of Trim32/ PKCζ axis in the regulation
of molecular signaling events that are responsible for the development of AD-like disease in mouse models, in
parallel to validation of findings in human AD patient samples. In view of our discoveries, we propose the
following aims: 1) Define the role of Trim32 in regulating a PKCζ mediated IL-4/Stat6 signaling pathway in
mouse models; 2) Investigate the molecular and structural basis of a homeostatic negative regulatory axis of
Trim32 and PKCζ; and 3) Evaluate the Trim32 and PKCζ axis in association with AD severity and AD
susceptibility to viral infection in humans. Our studies will incorporate Multiplex Immunohistochemistry Image
Cytometry for analysis of human skin biopsies and advanced imaging technologies to identify localization of
interacting proteins by super resolution microscopy, correlative light and electron microscopy, and molecular
structure analysis. This study will provide new insight for better understanding of the molecular mechanisms of
Th2 polarization underlying AD pathology and promises to improve prediction of patient severity of disease and
treatment response and to suggest novel intervention strategies to restore healthy immune and skin
homeostasis in AD patients.
项目摘要
特应性皮炎(AD)是一种先天免疫受损的炎性皮肤病,
易受细菌和病毒感染。尽管已经鉴定出了这些基因中的遗传多态性,
先天免疫信号通路,如TLR 1/2/6/9和NOD 1/2,先天免疫缺陷在
AD的发病机制仍然知之甚少。在这项研究中,我们提供了新的证据来支持
先天免疫缺陷在Th 2活化和AD发病机制中的作用
模特作为对咪喹莫特局部应用的响应,咪喹莫特是一种用于已建立的免疫缺陷综合征的Toll样受体激动剂。
在银屑病模型中,我们观察到Trim 32缺陷小鼠反而发展出AD样表型,包括
嗜酸性粒细胞和肥大细胞的真皮浸润,Th 2细胞因子产生增加,血清IgE升高,
与Trim 32-感受态野生型同窝仔中预期的Th 17应答相比。基于此,我们
假设Trim 32(一种具有天然抗病毒活性的E3泛素连接酶)调节宿主体内的稳态
此外,Trim 32途径蛋白质或功能性的缺陷可导致对感染的应答,
Th 2特应性表型。在寻找Trim 32底物蛋白可能负责特应性特征,在这些
在小鼠和人类AD中,我们为Trim 32调节蛋白激酶PKC β提供了新的证据,
信号级联的Stat 6激活剂,最终导致T细胞中IL-4/IL-5的表达和B的IgE产生
小鼠过敏模型中的细胞。因此,我们建议解决Trim 32/ PKC β轴在调节中的作用,
在小鼠模型中负责AD样疾病发展的分子信号事件,
与人AD患者样品中发现的验证平行。鉴于我们的发现,我们提出
以下目的:1)确定Trim 32在调节PKC β介导的IL-4/Stat 6信号通路中的作用,
小鼠模型; 2)研究体内稳态负调控轴的分子和结构基础,
Trim 32和PKC β轴;和3)评估Trim 32和PKC β轴与AD严重程度和AD
人类对病毒感染的易感性。我们的研究将结合多重免疫组织化学图像
用于分析人类皮肤活检的细胞计数法和先进的成像技术,
通过超分辨率显微镜、相关光学显微镜和电子显微镜以及分子生物学技术,
结构分析本研究将为更好地理解细胞凋亡的分子机制提供新的见解。
Th 2极化是AD病理学的基础,有望改善对患者疾病严重程度的预测,
治疗反应,并提出新的干预策略,以恢复健康的免疫和皮肤
AD患者的体内平衡。
项目成果
期刊论文数量(4)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Synergistic induction of IL-23 by TNFα, IL-17A, and EGF in keratinocytes.
角质形成细胞中TNFα,IL-17A和EGF对IL-23的协同诱导。
- DOI:10.1016/j.cyto.2020.155357
- 发表时间:2021-03
- 期刊:
- 影响因子:3.8
- 作者:Ehst B;Wang Z;Leitenberger J;McClanahan D;De La Torre R;Sawka E;Ortega-Loayza AG;Strunck J;Greiling T;Simpson E;Liu Y
- 通讯作者:Liu Y
NETosis Is Induced by Complement Component 5a: Implications in the Pathogenesis of Pyoderma Gangrenosum.
NETosis 由补体成分 5a 诱导:对坏疽性脓皮病发病机制的影响。
- DOI:10.1016/j.jid.2023.06.204
- 发表时间:2024
- 期刊:
- 影响因子:0
- 作者:Wang,Zhiping;Hornick,Noah;Vague,Morgan;Yang,Doris;Keller,Jesse;Kody,Shannon;Leachman,Sancy;Ortega-Loayza,AlexG;Liu,Yuangang
- 通讯作者:Liu,Yuangang
Inverse Correlation of TRIM32 and Protein Kinase C ζ in T Helper Type 2-Biased Inflammation.
- DOI:10.1016/j.jid.2020.09.021
- 发表时间:2021-05
- 期刊:
- 影响因子:0
- 作者:Wang Z;Yoo YJ;De La Torre R;Topham C;Hanifin J;Simpson E;Messing RO;Kulesz-Martin M;Liu Y
- 通讯作者:Liu Y
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
YUANGANG LIU其他文献
YUANGANG LIU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('YUANGANG LIU', 18)}}的其他基金
PIASy as a negative regulator of Th17 pathway in psoriasis
PIASy 作为银屑病 Th17 通路的负调节因子
- 批准号:
9089602 - 财政年份:2014
- 资助金额:
$ 35.88万 - 项目类别:
PIASy as a negative regulator of Th17 pathway in psoriasis
PIASy 作为银屑病 Th17 通路的负调节因子
- 批准号:
8769925 - 财政年份:2014
- 资助金额:
$ 35.88万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 35.88万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 35.88万 - 项目类别:
Grant-in-Aid for Scientific Research (C)